Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:HYPD NASDAQ:IMUX NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.99-2.0%$2.60$1.29▼$3.23$188.16M2.74449,676 shs275,728 shsHYPDHyperion DeFi$3.53+9.0%$3.58$2.49▼$17.18$53.51M2.47468,793 shs2.97 million shsIMUXImmunic$14.20+3.6%$12.01$5.06▼$15.77$193.42M1.37317,339 shs129,476 shsNKTXNkarta$2.64+0.8%$2.83$1.63▼$3.65$188.88M0.91764,995 shs555,962 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+0.50%+0.50%-26.18%-6.45%+23.03%HYPDHyperion DeFi+10.96%+25.10%-3.57%-14.06%+9.09%IMUXImmunic-2.14%+11.83%+13.49%+19.22%+67.09%NKTXNkarta-4.38%+6.94%-0.76%+16.96%+38.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.99-2.0%$2.60$1.29▼$3.23$188.16M2.74449,676 shs275,728 shsHYPDHyperion DeFi$3.53+9.0%$3.58$2.49▼$17.18$53.51M2.47468,793 shs2.97 million shsIMUXImmunic$14.20+3.6%$12.01$5.06▼$15.77$193.42M1.37317,339 shs129,476 shsNKTXNkarta$2.64+0.8%$2.83$1.63▼$3.65$188.88M0.91764,995 shs555,962 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+0.50%+0.50%-26.18%-6.45%+23.03%HYPDHyperion DeFi+10.96%+25.10%-3.57%-14.06%+9.09%IMUXImmunic-2.14%+11.83%+13.49%+19.22%+67.09%NKTXNkarta-4.38%+6.94%-0.76%+16.96%+38.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.80Moderate Buy$5.00151.26% UpsideHYPDHyperion DeFi 2.25Hold$5.6560.06% UpsideIMUXImmunic 3.00Buy$47.57235.01% UpsideNKTXNkarta 2.80Moderate Buy$10.75307.20% UpsideCurrent Analyst Ratings BreakdownLatest HYPD, CGEN, IMUX, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.305/29/2026IMUXImmunic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/22/2026IMUXImmunic Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/22/2026IMUXImmunic B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $27.005/21/2026CGENCompugen Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $5.005/20/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/14/2026IMUXImmunic Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/4/2026IMUXImmunic Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.66M2.59$0.37 per share5.41$1.09 per share1.83HYPDHyperion DeFi$1.04M51.30N/AN/A$4.73 per share0.75IMUXImmunicN/AN/AN/AN/A($0.55) per shareN/ANKTXNkartaN/AN/AN/AN/A$4.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.375.38N/AN/A47.97%47.72%27.51%8/5/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A3.07N/AN/A-91.59%-73.08%N/AIMUXImmunic-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%8/6/2026 (Estimated)NKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)Latest HYPD, CGEN, IMUX, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07-$0.08-$0.01-$0.08$1.57 million$2.18 million5/13/2026Q1 2026IMUXImmunic-$0.71-$1.08-$0.37-$1.08N/AN/A5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A3/26/2026Q4 2025HYPDHyperion DeFiN/A-$7.76N/A-$7.76N/A$0.50 million3/25/2026Q4 2025NKTXNkarta-$0.32-$0.37-$0.05-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.236.23HYPDHyperion DeFi0.121.971.97IMUXImmunicN/A4.924.92NKTXNkartaN/A12.9612.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%HYPDHyperion DeFi25.84%IMUXImmunic51.82%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%HYPDHyperion DeFi7.50%IMUXImmunic5.49%NKTXNkarta9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableHYPDHyperion DeFi4015.16 million14.02 millionNo DataIMUXImmunic7013.62 million12.87 millionOptionableNKTXNkarta14071.55 million64.53 millionOptionableHYPD, CGEN, IMUX, and NKTX HeadlinesRecent News About These CompaniesNkarta Shareholders Back Directors, Auditor and Annual Say-on-PayJune 11, 2026 | tipranks.comNkarta Inc Ordinary Shares NKTXMay 16, 2026 | morningstar.comMHere's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn SituationMay 14, 2026 | finance.yahoo.comNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)April 23, 2026 | theglobeandmail.comNKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramApril 17, 2026 | zacks.comNkarta rises on FDA agreement for amended trial protocolApril 16, 2026 | msn.comNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersApril 15, 2026 | globenewswire.comNkarta to Participate in Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comNkarta Launches $100 Million At-the-Market Stock OfferingMarch 26, 2026 | tipranks.comNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsMarch 25, 2026 | globenewswire.comNkarta to Participate in March Investor ConferencesFebruary 27, 2026 | globenewswire.comInsider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of StockJanuary 21, 2026 | insidertrades.comWe Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth CarefullyDecember 4, 2025 | finance.yahoo.comNkarta to Participate in Evercore Healthcare ConferenceDecember 2, 2025 | globenewswire.comNkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real ReasonNovember 22, 2025 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB) and Nkarta (NKTX)November 11, 2025 | theglobeandmail.comNkarta price target lowered to $11 from $12 at StifelNovember 11, 2025 | msn.comNkarta Advances NKX019 Program Amid Financial StabilityNovember 11, 2025 | msn.comNkarta reports Q3 EPS (29c), consensus (30c)November 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYPD, CGEN, IMUX, and NKTX Company DescriptionsCompugen NASDAQ:CGEN$1.99 -0.04 (-1.97%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.01 (+0.25%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Hyperion DeFi NASDAQ:HYPD$3.53 +0.29 (+8.95%) Closing price 04:00 PM EasternExtended Trading$3.53 0.00 (0.00%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Immunic NASDAQ:IMUX$14.20 +0.49 (+3.57%) Closing price 04:00 PM EasternExtended Trading$14.20 +0.01 (+0.04%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Nkarta NASDAQ:NKTX$2.64 +0.02 (+0.76%) Closing price 04:00 PM EasternExtended Trading$2.62 -0.02 (-0.95%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
